Rigel Pharmaceuticals (RIGL) PT Raised to $11 at Piper Jaffray
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and raised his price target to $11.00 (from $10.00) following data this morning.
Shares of Rigel Pharmaceuticals closed at $2.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Imperial Capital Raises Price Target on Spirit Airlines (SAVE); Cuts 4Q Estimates
- FBR Capital Remains Bullish Following Select Income REIT's (SIR) 3Q Miss
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA, Momentum Movers, Trader Talk
Related EntitiesPiper Jaffray, Joshua Schimmer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!